Development and Validation of a Nomogram for Predicting Tigecycline-Related Coagulopathy: A Retrospective Cohort Study

References

• World Health Organization. Guidelines for the Prevention and Control of Carbapenem-Resistant Enterobacteriaceae, Acinetobacter Baumannii and Pseudomonas Aeruginosa in Health Care Facilities. Geneva: World Health Organization; 2017.
   Google Scholar
• Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–655. doi:10.1016/S0140-6736(21)02724-0
   PubMed Web of Science ®Google Scholar
• Nowak J, Zander E, Stefanik D, et al. High incidence of pandrug-resistant Acinetobacter baumannii isolates collected from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial. J Antimicrob Chemother. 2017;72(12):3277–3282. doi:10.1093/jac/dkx322
   PubMed Web of Science ®Google Scholar
• Karageorgopoulos DE, Falagas ME. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis. 2008;8(12):751–762. doi:10.1016/S1473-3099(08)70279-2
   PubMed Web of Science ®Google Scholar
• Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, Pascual A. Treatment of infections caused by extended-spectrum-beta-lactamase-, Ampc-, and carbapenemase-producing Enterobacteriaceae. Clin Microbiol Rev. 2018;31(2). doi:10.1128/CMR.00079-17
   PubMed Web of Science ®Google Scholar
• Ni W, Han Y, Zhao J, et al. Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis. Int J Antimicrob Agents. 2016;47(2):107–116. doi:10.1016/j.ijantimicag.2015.11.011
   PubMed Web of Science ®Google Scholar
• McGovern PC, Wible M, El-Tahtawy A, Biswas P, Meyer RD. All-cause mortality imbalance in the tigecycline Phase 3 and 4 clinical trials. Int J Antimicrob Agents. 2013;41(5):463–467. doi:10.1016/j.ijantimicag.2013.01.020
   PubMed Web of Science ®Google Scholar
• Tasina E, Haidich AB, Kokkali S, Arvanitidou M. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis. 2011;11(11):834–844. doi:10.1016/S1473-3099(11)70177-3
   PubMed Web of Science ®Google Scholar
• Cui N, Cai H, Li Z, Lu Y, Wang G, Lu A. Tigecycline-induced coagulopathy: a literature review. Int J Clin Pharm. 2019;41(6):1408–1413. doi:10.1007/s11096-019-00912-5
   PubMed Web of Science ®Google Scholar
• Leng B, Xue YC, Zhang W, et al. Analysis of the effect of tigecycline on coagulation function. Chem Pharm Bull. 2019;67(3):258–264. doi:10.1248/cpb.c18-00844
   PubMed Web of Science ®Google Scholar
• Zhang Q, Zhou S, Zhou J. Tigecycline treatment causes a decrease in fibrinogen levels. Antimicrob Agents Chemother. 2015;59(3):1650–1655. doi:10.1128/AAC.04305-14
   PubMed Web of Science ®Google Scholar
• Akdağ D, Işıkgöz-Taşbakan M, Pullukcu H, Sipahi H, Sipahi OR. Tigecycline versus INR increase; more than expected? Expert Opin Drug Saf. 2020;19(3):335–337. doi:10.1080/14740338.2020.1723546
   PubMed Web of Science ®Google Scholar
• Hu J, Xiao Y-H, Zheng Y, Lai Y-X, Fang X-L, Fang Q. Clinical characteristics and risk factors of tigecycline-associated hypofibrinogenemia in critically ill patients. Eur J Clin Pharmacol. 2020;76(7):913–922. doi:10.1007/s00228-020-02860-w
   PubMed Web of Science ®Google Scholar
• Liu J, Yan Y, Zhang F. Risk factors for tigecycline-associated hypofibrinogenemia. Ther Clin Risk Manag. 2021;17:325–332. doi:10.2147/TCRM.S302850
   PubMed Web of Science ®Google Scholar
• Zhang Q, Wang J, Liu H, Ma W, Zhou S, Zhou J. Risk factors for tigecycline-induced hypofibrinogenemia. J Clin Pharm Ther. 2020;45(6):1434–1441. doi:10.1111/jcpt.13250
   PubMed Web of Science ®Google Scholar
• Alba AC, Agoritsas T, Walsh M, et al. Discrimination and calibration of clinical prediction models: users’ guides to the medical literature. JAMA. 2017;318(14):1377–1384. doi:10.1001/jama.2017.12126
   PubMed Web of Science ®Google Scholar
• Brink AJ, Bizos D, Boffard KD, et al. Guideline: appropriate use of tigecycline. S Afr Med J. 2010;100(6 Pt 2):388–394. doi:10.7196/SAMJ.4109
   PubMed Web of Science ®Google Scholar
• Rodvold KA, McConeghy KW. Methicillin-resistant Staphylococcus aureus therapy: past, present, and future. Clin Infect Dis. 2014;58(Suppl 1):S20–27. doi:10.1093/cid/cit614
   PubMed Web of Science ®Google Scholar
• Bender JK, Cattoir V, Hegstad K, et al. Update on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe: towards a common nomenclature. Drug Resist Updat. 2018;40:25–39. doi:10.1016/j.drup.2018.10.002
   PubMed Web of Science ®Google Scholar
• Durante-Mangoni E, Andini R, Zampino R. Management of carbapenem-resistant Enterobacteriaceae infections. Clin Microbiol Infect. 2019;25(8):943–950. doi:10.1016/j.cmi.2019.04.013
   PubMed Web of Science ®Google Scholar
• Morosini MI, García-Castillo M, Coque TM, et al. Antibiotic coresistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline. Antimicrob Agents Chemother. 2006;50(8):2695–2699. doi:10.1128/AAC.00155-06
   PubMed Web of Science ®Google Scholar
• Karaiskos I, Lagou S, Pontikis K, Rapti V, Poulakou G. The “Old” and the “New” Antibiotics for MDR gram-negative pathogens: for whom, when, and how. Front Public Health. 2019;7:151. doi:10.3389/fpubh.2019.00151
   PubMed Web of Science ®Google Scholar
• Kadoyama K, Sakaeda T, Tamon A, Okuno Y. Adverse event profile of tigecycline: data mining of the public version of the U.S. Food and Drug Administration adverse event reporting system. Biol Pharm Bull. 2012;35(6):967–970. doi:10.1248/bpb.35.967
   PubMed Web of Science ®Google Scholar
• Pieringer H, Schmekal B, Biesenbach G, Pohanka E. Severe coagulation disorder with hypofibrinogenemia associated with the use of tigecycline. Ann Hematol. 2010;89(10):1063–1064. doi:10.1007/s00277-010-0911-7
   PubMed Web of Science ®Google Scholar
• Rossitto G, Piano S, Rosi S, Simioni P, Angeli P. Life-threatening coagulopathy and hypofibrinogenemia induced by tigecycline in a patient with advanced liver cirrhosis. Eur J Gastroenterol Hepatol. 2014;26(6):681–684. doi:10.1097/MEG.0000000000000087
   PubMed Web of Science ®Google Scholar
• Sabanis N, Paschou E, Gavriilaki E, Kalaitzoglou A, Vasileiou S. Hypofibrinogenemia induced by tigecycline: a potentially life-threatening coagulation disorder. Infect Dis. 2015;47(10):743–746. doi:10.3109/23744235.2015.1043942
   PubMed Web of Science ®Google Scholar
• Giryes S, Azzam ZS, Ismael-Badarneh R, Krivoy N, Berger G. Severe coagulation disorder and thrombocytopenia associated with tigecycline - case report and review of literature. Curr Drug Saf. 2017;12(1):7–9. doi:10.2174/1574886311666160920090714
   PubMed Web of Science ®Google Scholar
• McMahan J, Moenster RP. Tigecycline-induced coagulopathy. Am J Health Syst Pharm. 2017;74(3):130–134. doi:10.2146/ajhp150894
   PubMed Web of Science ®Google Scholar
• Wu X, Zhao P, Dong L, Zhang X. A case report of patient with severe acute cholangitis with tigecycline treatment causing coagulopathy and hypofibrinogenemia. Medicine. 2017;96(49):e9124. doi:10.1097/MD.0000000000009124
   PubMed Web of Science ®Google Scholar
• Wu P-C, Wu -C-C. Tigecycline-associated hypofibrinogenemia: a case report and review of the literature. IDCases. 2018;11:56–57. doi:10.1016/j.idcr.2018.01.003
   PubMed Web of Science ®Google Scholar
• Akalay S, Vanassche T, De Munter P. Tigecycline-induced life-threatening coagulopathy in a patient with a Mycobacterium abscess: a case report and step-by-step diagnostic approach. Acta Clin Belg. 2021;76(5):410–414. doi:10.1080/17843286.2020.1747197
   PubMed Web of Science ®Google Scholar
• Fan Q, Huang W, Weng Y, Xie X, Shi Z. Hypofibrinogenemia induced by high-dose tigecycline-case report and review of literature. Medicine. 2020;99(43):e22638. doi:10.1097/MD.0000000000022638
   PubMed Web of Science ®Google Scholar
• Guo M, Liang J, Li D, et al. Coagulation dysfunction events associated with tigecycline: a real-world study from FDA adverse event reporting system (FAERS) database. Thromb J. 2022;20(1):12. doi:10.1186/s12959-022-00369-z
   PubMed Web of Science ®Google Scholar
• Wang D, Lin C, Gu C, Wu Y, Wang S. Tigecycline-associated coagulopathy: a single-center retrospective analysis. Pharmacology. 2022;107(9–10):524–536. doi:10.1159/000525380
   PubMed Web of Science ®Google Scholar
• Treml B, Rajsic S, Hell T, Fries D, Bachler M. Progression of fibrinogen decrease during high dose tigecycline therapy in critically ill patients: a retrospective analysis. J Clin Med. 2021;10(20):4702. doi:10.3390/jcm10204702
   PubMed Web of Science ®Google Scholar
• Brandtner A, Bachler M, Fries D, et al. Tigecycline interferes with fibrinogen polymerization independent of peripheral interactions with the coagulation system. Antibiotics. 2020;9(2):84. doi:10.3390/antibiotics9020084
   Google Scholar